Key facts
- Notable investors include Transpose Platform Management, Entrepreneurs First, Boost VC, PC'up Incubator, Station F.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for A51 Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for A51 Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About A51 Therapeutics
Developer of programmable molecular agents designed for therapeutic intervention in complex biological systems. The company's platform integrates computational modelling, high-throughput cellular assays, and precision micro fluid workflows to construct and test nucleic acid-based, enabling biomedical researchers and pharmaceutical developers to identify functional targets, optimize molecular interactions, and accelerate the development of re nucleic therapies for genetically linked diseases.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2025
- Employees
- 6
- Website
- a51tx.com/
- Ownership
- Privately Held (backing)
A51 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in A51 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on A51 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.